FDA bans import of 28 generic drugs manufactured in India

The Food and Drug Administration halted the importation of drugs manufactured by Ranbaxy Laboratories because of deficiences found at two of the company's plants.  It claimed the drugs had caused  no harm to consumers and the action was "preventative".  It also claimed that on testing, the drugs have not been found to be contaminated, sub-potent or unsafe. 

The Agency had sent two warning letters to the manufacturer, the first in 2006, warning of deviations from "current good manufacturing process".  The deficiencies related to "inadequate sterile processing  operations" and inadequate record-keeping.  The medications included antiretroviral AZT, antibiotics, antivirals, and medications for high cholesterol, diabetes, high blood pressure, seasonal allergies and acne.